Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools

Fig. 5

Notch, C-KIT, MAPK, PI3K and PARP inhibition reduces tumorsphere formation in ovary tumor cells. a Tumorsphere formation in OVCAR8 and SKOV3 cells treated with cis-platin (IC30; 0.3 μM), with or without gamma-secretase inhibitor DAPT (5 μM), tyrosine kinase inhibitor Imatinib (8 μM), PARP inhibitor olaparib (10 μM), MAPK inhibitor PD98059 (15 μM) or PI3K inhibitor BEZ235 (10 μM). b Tumorsphere formation in OVCAR8 and SKOV3 cells treated with carboplatin (IC30; 0.3 μM), with or without the inhibitors described in (A). The average and SD of at least three independent experiments are shown. Statistical significance was assessed using the Student’s t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001

Back to article page